Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response

Ewa Wojcik, Jan Kanty Kulpa Department of Clinical Biochemistry, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow, Poland Abstract: Lung cancer belongs to malignant tumors that possess the highest rates of morbidity and mortality in the world. A number of morp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wojcik E, Kulpa JK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	small-cell lung cancer tumor markers predictive and prognostic values Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ea2d2ea8ebc541d28130334646b8eb47
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea2d2ea8ebc541d28130334646b8eb47
record_format	dspace
spelling	oai:doaj.org-article:ea2d2ea8ebc541d28130334646b8eb472021-12-02T06:08:01ZPro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response1179-2728https://doaj.org/article/ea2d2ea8ebc541d28130334646b8eb472017-11-01T00:00:00Zhttps://www.dovepress.com/pro-gastrin-releasing-peptide-progrp-as-a-biomarker-in-small-cell-lung-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Ewa Wojcik, Jan Kanty Kulpa Department of Clinical Biochemistry, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow, Poland Abstract: Lung cancer belongs to malignant tumors that possess the highest rates of morbidity and mortality in the world. A number of morphological, biological and clinical features justify the distinction of small-cell carcinoma with respect to the other histological types of lung cancer. The predominant neuroendocrine phenotype is critical for the selection of biomarkers used in diagnostics, monitoring and evaluation of treatment response; early onset relapses in patients with small-cell lung cancer (SCLC) and the evaluation of their prognosis. Although for a long time the neuron-specific enolase (NSE) was considered to be the marker of choice for this tumor, it is now increasingly important to pay attention to concentrations of pro-gastrin-releasing peptide (ProGRP). The results of this marker have been implicated in the differential diagnosis of non-small lung cancer and SCLC, chemotherapy and radiotherapy monitoring as well as evaluation of treatment response. The subject of this series of studies is to determine the usefulness of ProGRP in the evaluation of patients’ prognosis and its predictive value. The current aim for the optimization of the effectiveness of biochemical diagnostics of SCLC is recommended by complementary ProGRP and NSE studies. The present work is a summary of the latest reports regarding diagnostic utility of these markers in SCLC. Keywords: small-cell lung cancer, tumor markers, predictive and prognostic valuesWojcik EKulpa JKDove Medical Pressarticlesmall-cell lung cancertumor markerspredictive and prognostic valuesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 231-240 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	small-cell lung cancer tumor markers predictive and prognostic values Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	small-cell lung cancer tumor markers predictive and prognostic values Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Wojcik E Kulpa JK Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
description	Ewa Wojcik, Jan Kanty Kulpa Department of Clinical Biochemistry, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow, Poland Abstract: Lung cancer belongs to malignant tumors that possess the highest rates of morbidity and mortality in the world. A number of morphological, biological and clinical features justify the distinction of small-cell carcinoma with respect to the other histological types of lung cancer. The predominant neuroendocrine phenotype is critical for the selection of biomarkers used in diagnostics, monitoring and evaluation of treatment response; early onset relapses in patients with small-cell lung cancer (SCLC) and the evaluation of their prognosis. Although for a long time the neuron-specific enolase (NSE) was considered to be the marker of choice for this tumor, it is now increasingly important to pay attention to concentrations of pro-gastrin-releasing peptide (ProGRP). The results of this marker have been implicated in the differential diagnosis of non-small lung cancer and SCLC, chemotherapy and radiotherapy monitoring as well as evaluation of treatment response. The subject of this series of studies is to determine the usefulness of ProGRP in the evaluation of patients’ prognosis and its predictive value. The current aim for the optimization of the effectiveness of biochemical diagnostics of SCLC is recommended by complementary ProGRP and NSE studies. The present work is a summary of the latest reports regarding diagnostic utility of these markers in SCLC. Keywords: small-cell lung cancer, tumor markers, predictive and prognostic values
format	article
author	Wojcik E Kulpa JK
author_facet	Wojcik E Kulpa JK
author_sort	Wojcik E
title	Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
title_short	Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
title_full	Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
title_fullStr	Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
title_full_unstemmed	Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
title_sort	pro-gastrin-releasing peptide (progrp) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/ea2d2ea8ebc541d28130334646b8eb47
work_keys_str_mv	AT wojcike progastrinreleasingpeptideprogrpasabiomarkerinsmallcelllungcancerdiagnosismonitoringandevaluationoftreatmentresponse AT kulpajk progastrinreleasingpeptideprogrpasabiomarkerinsmallcelllungcancerdiagnosismonitoringandevaluationoftreatmentresponse
_version_	1718400085783478272

Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response

Ejemplares similares